Vomiting Syndrome Skyrockets: A Cannabis Crisis

Man,Suffering,From,Sick,Stomach,And,Vomiting

Emergency rooms across America are battling a mysterious, cannabis-linked vomiting syndrome that has surged by 650% since 2016. The World Health Organization has now officially recognized Cannabis Hyperemesis Syndrome (CHS) with its own diagnostic code (R11.16), forcing a long-overdue discussion about the dangerous, skyrocketing potency of modern marijuana products. This official recognition will enable systematic tracking of the condition, which is disproportionately affecting young adults and raising uncomfortable questions for advocates of current legalization policies.

Story HIghlights

Cannabis hyperemesis syndrome (CHS) received its first-ever official WHO diagnostic code (R11.16) in October 2025, enabling systematic tracking of a condition previously misdiagnosed as food poisoning.
Emergency room visits for CHS have skyrocketed 650% from 2016 baseline levels, with the surge accelerating during the COVID-19 pandemic and remaining elevated.
Modern cannabis products exceed 20% THC potency compared to 5% in the 1990s, with concentrated products reaching 90% THC—a dramatic increase linked to CHS prevalence among users aged 18-35.
The condition causes severe, intractable nausea and vomiting that paradoxically worsens despite cannabis’s reputation as an anti-nausea treatment, with some cases resulting in kidney failure, seizures, and death.

A Condition Finally Gets Its Name

For years, emergency room physicians struggled to diagnose a debilitating condition affecting chronic cannabis users: severe, uncontrollable vomiting that defied conventional treatment and mystified both patients and doctors. Without a formal diagnostic code, cases were scattered across medical records under generic vomiting categories, making epidemiological tracking impossible. The World Health Organization’s October 2025 decision to assign cannabis hyperemesis syndrome its own ICD-10 diagnostic code (R11.16) represents the first official global recognition of this condition, fundamentally changing how healthcare systems identify and monitor the syndrome.

Chronic cannabis users with persistent vomiting, nausea and abdominal pain can now be properly diagnosed and tracked, thanks to a new official code from the World Health Organization.https://t.co/Ct97EebUBd

— Fox News Health (@foxnewshealth) November 30, 2025

The timing of this recognition coincides with alarming data: a November 2025 JAMA Network Open study documented a 650% increase in CHS-related emergency room visits from 2016 to pandemic peak levels, with cases remaining elevated through 2025. This surge reflects not merely increased awareness but a genuine explosion in the condition’s prevalence, particularly among younger adults aged 18 to 35 who have grown up with access to increasingly potent cannabis products.

The Potency Problem Nobody Wants to Discuss

The elephant in the room is product potency. In the 1990s, typical cannabis products contained approximately 5% THC. Today’s recreational products routinely exceed 20% THC, with concentrated products reaching 90% or higher. This exponential increase in potency has fundamentally altered the risk profile for chronic users, yet legalization advocates rarely acknowledge this critical distinction. Cannabis products used medically for nausea typically contain less than 5% THC, suggesting that potency itself may be the determining factor in whether cannabis triggers therapeutic effects or causes severe harm.

John Puls, a nationally certified addiction specialist, characterizes the CHS surge as “alarming,” particularly among adolescents and young adults. He directly links increased CHS rates to high-potency cannabis products and emphasizes that the most common misconception about CHS—that it is not a real condition—has been perpetuated by the lack of formal diagnostic recognition. For Puls and other clinical practitioners, the WHO code represents “a significant step in the right direction” in acknowledging the real dangers of high-potency cannabis.

A Paradox That Defies Common Sense

Cannabis hyperemesis syndrome represents a cruel paradox: while cannabis is commonly used medically to treat nausea and vomiting, chronic heavy use can trigger the opposite physiological response—severe, intractable nausea and vomiting that becomes progressively worse. Patients experience what clinicians call “scromiting” (screaming and vomiting simultaneously), yet find temporary relief through a counterintuitive method: prolonged hot showers. Some patients have used cannabis without problems for decades before suddenly becoming susceptible, suggesting that individual vulnerability factors remain incompletely understood.

The condition’s severity cannot be overstated. The National Institutes of Health recognizes CHS as a dangerous and potentially deadly syndrome that can cause severe nausea, repeated vomiting, abdominal pain, dehydration, weight loss, and in rare cases, heart rhythm problems, seizures, kidney failure, and death. Dr. Chris Buresh, an emergency medicine specialist at the University of Washington, notes that “even small amounts can make these people start throwing up” once they have experienced CHS, trapping patients in a cycle where continued cannabis use perpetuates the condition.

What the New Diagnostic Code Actually Changes

The practical impact of the WHO code extends beyond academic recognition. Healthcare systems are now implementing the new diagnostic code into electronic health record systems and billing processes, enabling direct diagnosis recording rather than the previous practice of using combination codes for nausea plus cannabis use indicators. This transition will dramatically improve data quality and consistency across healthcare institutions, providing epidemiologists and public health officials with reliable information about disease burden and trends for the first time.

Beatriz Carlini, research associate professor at the University of Washington School of Medicine, emphasizes that the new diagnostic code “will supply important hard evidence on cannabis-adverse events, which physicians tell us is a growing problem.” She notes that the code “helps us count and monitor these cases,” highlighting the surveillance benefits of formal recognition. The improved diagnostic accuracy will also reduce the months or years of diagnostic delays that previously characterized CHS cases, enabling earlier intervention and appropriate treatment recommendations—primarily cannabis cessation.

The Uncomfortable Questions About Legalization

The CHS surge raises uncomfortable questions about cannabis legalization policies that have prioritized market expansion over potency regulation. As cannabis becomes increasingly legal and socially normalized, consumption patterns have shifted, with greater access to high-potency products and more frequent use among certain demographics. The condition disproportionately affects younger users, suggesting that legalization has created a public health vulnerability among the population least equipped to understand product risks.

Public health advocates may cite CHS prevalence data to argue for stricter potency regulations or age restrictions, yet legalization advocates continue to argue that education and responsible use can mitigate risks. The research community maintains scientific caution about definitive claims regarding cannabis-CHS relationships, acknowledging that causation remains unproven and underlying mechanisms are incompletely understood. However, the convergence of evidence—650% increase in ER visits, documented correlation with high-potency products, and clinical observations of severe health consequences—suggests that potency-based regulation deserves serious policy consideration.

Watch the report: When Cannabis Triggers Hyperemesis in Youth